Tillkännagivande • Apr 11
e-therapeutics plc Considers Switching Its Listing to New York Shares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9. Tillkännagivande • Apr 10
e-therapeutics plc, Annual General Meeting, Apr 29, 2024 e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom New Risk • Feb 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£77.1m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$430k). Minor Risk Market cap is less than US$100m (UK£77.1m market cap, or US$97.7m). Tillkännagivande • Dec 27
e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States e-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market. New Risk • Nov 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$421k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£67.3m market cap, or US$83.3m). Tillkännagivande • Oct 20
e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023 e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023 Tillkännagivande • Sep 21
E-Therapeutics plc Announces Senior Management Update e-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales. Tillkännagivande • May 11
e-therapeutics plc, Annual General Meeting, Jul 18, 2023 e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters. Reported Earnings • May 07
Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022) Full year 2023 results: UK£0.015 loss per share. Net loss: UK£8.27m (loss widened 2.5% from FY 2022). Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 30
First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022) First half 2023 results: UK£0.007 loss per share (further deteriorated from UK£0.005 loss in 1H 2022). Net loss: UK£3.81m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 87% per year, which means it is well ahead of earnings. Tillkännagivande • May 17
e-therapeutics plc, Annual General Meeting, Jul 19, 2022 e-therapeutics plc, Annual General Meeting, Jul 19, 2022, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington London United Kingdom Reported Earnings • May 05
Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021) Full year 2022 results: UK£0.016 loss per share (down from UK£0.01 loss in FY 2021). Net loss: UK£8.07m (loss widened 119% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 129% per year, which means it is well ahead of earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 28
First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021) First half 2022 results: Net loss: UK£2.79m (loss widened 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Oct 28
CEO & Director recently bought UK£100k worth of stock On the 26th of October, Ahmad Mortazavi bought around 275k shares on-market at roughly UK£0.36 per share. This was the largest purchase by an insider in the last 3 months. This was Ahmad's only on-market trade for the last 12 months. Reported Earnings • May 15
Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020) Full year 2021 results: Net loss: UK£3.68m (loss widened 57% from FY 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 15
e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million. e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 93,750,000
Price\Range: £0.24
Transaction Features: Regulation S; Subsequent Direct Listing Tillkännagivande • Mar 01
e-Therapeutics plc Announces Board Changes e-therapeutics plc announced the following changes to its Board of Directors. With immediate effect, the role of Executive Chairman and Chief Executive will be split so that Professor Trevor Jones, an Independent Non-Executive Director of the Company since 2015, will assume the role of Independent Non-Executive Chairman and Ali Mortazavi will continue in his role as Chief Executive Officer. Trevor has over 40 years' experience in the pharmaceutical and biotechnology industries as well as in academia. He has held significant roles including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal and Malarone. He is Visiting Professor at King's College, London and holds honorary degrees and Gold Medals from seven universities. Is New 90 Day High Low • Feb 04
New 90-day high: UK£0.22 The company is up 67% from its price of UK£0.13 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. Tillkännagivande • Feb 03
e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modality e-therapeutics plc announced the addition of its RNAi platform as a therapeutic drug modality. The Company has recently filed a patent application related to the chemistry of novel GalNAc-conjugated siRNAs (short interfering RNA), an important element of its RNAi platform that enables specific hepatocyte targeting for liver gene silencing. In addition, a number of siRNA constructs have been designed with potentially beneficial safety and potency profiles and additional patent applications are expected to be filed shortly. The company believes that the new patent applications, combined with know-how, will provide a significant competitive advantage in RNAi. The new constructs will include features to minimise potential microRNA off-target effects, thermally destabilising regions of the siRNA for reduced toxicity and important position-specific stabilisation chemistries to improve potency. Multiple in vitro and in vivo experiments are underway to test these constructs with contract research organizations in Germany and China. Is New 90 Day High Low • Jan 09
New 90-day high: UK£0.21 The company is up 37% from its price of UK£0.15 on 09 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Tillkännagivande • Dec 11
e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platform e-therapeutics plc announced the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform. In March 2020, the Company announced its intention to deploy its network biology platform to identify clinical stage compounds that either singly or in combination could be repurposed rapidly to treat COVID-19. To approach this by focussing on therapeutic strategies that target host systems, thereby minimising the risk of resistance and potentially being effective for the treatment of other viral infections. From previous work using network models of SIRS (Systemic inflammatory response syndrome) seen in indications such as sepsis, had identified a class of small molecule compounds, a mechanism and target that was able to silence the 'cytokine storm' generated in human blood cells by a range of inflammatory triggers. In March 2020, undertook an in silico analysis of data sets from human cells infected with SARS-CoV-2 and generated network models of the cellular machinery that the virus had 'hijacked'. Analysis of both SIRS work and the SARS-CoV-2 networks revealed a key common process which was simultaneously important to the virus and the hyperinflammatory response. Platform predicted that inhibition of the same target, GRP94, that was effective in suppressing hyperinflammation would also be effective in disrupting the virus's ability to replicate. In May 2020, small molecule compounds predicted by platform were tested in validated SARS-CoV-2 in vitro assays at WuXi AppTech. These compounds showed potent anti-inflammatory and anti-viral activity. Report here that in vitro assays have confirmed in silico predictions and have identified a clear mechanism, target and clinical stage compounds. These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus. The clinical stage compounds identified have been developed in humans for alternative indications and have an established safety profile in man. These, and other selective compounds sharing this target, could be rapidly deployed into clinical trials to treat patients with serious Covid-19 disease. Given mechanistic insights, it would also be feasible to develop novel, highly selective drugs against GRP94. Continue to work on repurposable combinations using platform and have compound combinations currently in testing. Reported Earnings • Oct 13
First half earnings released Over the last 12 months the company has reported total losses of UK£3.41m, with losses widening by 9.7% from the prior year. Tillkännagivande • Oct 13
e-therapeutics plc Announces Appointment of Ali Mortazavi as CEO e-therapeutics plc announced the appointment of Ali Mortazavi as Chief Executive Officer. He will also retain his position as Chairman of the Company. The Board currently consists of one Executive Director and two Non-Executive Directors. Tillkännagivande • Oct 07
e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020 e-therapeutics plc announced that they will report first half, 2020 results on Oct 12, 2020 Tillkännagivande • Sep 28
e-therapeutics plc Announces Executive Changes e-therapeutics plc announced the expansion of its Scientific Advisory Board with the appointment of Bill Harte and Professor John Mattick. The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Paul Burke as Chair following the Company's expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes. Dr. Bill Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients. Tillkännagivande • Jul 09
e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million. e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,250,000
Price\Range: £0.12 